Get the Stockscreener App
19.72
2.33%
-0.47
Pre-market:
20.16
0.44
+2.23%
Arcus Biosciences Inc stock is traded at $19.72, with a volume of 5.33M.
It is down -2.33% in the last 24 hours and up +45.00% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$20.19
Open:
$18.54
24h Volume:
5.33M
Relative Volume:
4.99
Market Cap:
$2.10B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-6.3819
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
+13.92%
1M Performance:
+45.00%
6M Performance:
+125.37%
1Y Performance:
+28.89%
1-Day Range:
$18.32
$19.99
1-Week Range:
$17.45
$22.11
52-Week Range:
$6.50
$22.11
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
19.72 | 2.15B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
What dividend safety score for Arcus Biosciences Inc. stockJuly 2025 Market Mood & Weekly High Potential Stock Alerts - newser.com
Risk adjusted return profile for Arcus Biosciences Inc. analyzedWeekly Investment Summary & AI Forecasted Entry and Exit Points - newser.com
Why Arcus Biosciences Inc. stock is rated strong buyJuly 2025 Patterns & Technical Confirmation Trade Alerts - newser.com
Price action breakdown for Arcus Biosciences Inc.Weekly Investment Summary & Stock Timing and Entry Methods - newser.com
Automated trading signals detected on Arcus Biosciences Inc.2025 Risk Factors & Safe Capital Allocation Plans - newser.com
Arcus Biosciences (NYSE:RCUS) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Visual analytics tools that track Arcus Biosciences Inc. performance2025 Price Targets & High Accuracy Trade Alerts - newser.com
Analyzing recovery setups for Arcus Biosciences Inc. investorsWeekly Investment Recap & High Accuracy Trade Signal Alerts - newser.com
Arcus Biosciences (NYSE:RCUS) Shares Gap Down on Insider Selling - MarketBeat
Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported, And Analysts Assigned A US$29.60 Price Target - simplywall.st
Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
FY2025 EPS Estimates for RCUS Increased by Analyst - MarketBeat
Wedbush Increases Earnings Estimates for Arcus Biosciences - MarketBeat
HC Wainwright Has Positive Forecast for RCUS FY2025 Earnings - MarketBeat
Reversal indicators forming on Arcus Biosciences Inc. stockEarnings Beat & Safe Entry Zone Identification - newser.com
Why Arcus Biosciences Inc. stock appears on watchlistsJuly 2025 Fed Impact & Smart Investment Allocation Tips - newser.com
Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 19,019 Shares - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) President Sells 77,840 Shares of Stock - MarketBeat
Arcus Biosciences stock falls after pricing $250 million public offering By Investing.com - Investing.com Nigeria
Arcus Biosciences launches public offering of common stock By Investing.com - Investing.com Australia
Arcus Biosciences stock falls after pricing $250 million public offering - Investing.com
Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), TransMedics Group (TMDX) and Arcus Biosciences (RCUS) - The Globe and Mail
Arcus Biosciences (RCUS) Announces Pricing Details for Recent Of - GuruFocus
Arcus Biosciences (RCUS) Announces Pricing Details for Recent Offering - GuruFocus
Arcus Biosciences falls after $250 mln stock sale - TradingView
Is Arcus Biosciences Inc. stock safe for risk averse investorsJuly 2025 Fed Impact & High Accuracy Investment Signals - newser.com
Arcus Biosciences Prices $250 Million Common Stock Offering - MarketScreener
Arcus Biosciences Inc. recovery potential after sell offMarket Risk Summary & Safe Entry Trade Signal Reports - newser.com
Arcus Biosciences prices $250 million public offering at $18.25 per share By Investing.com - Investing.com South Africa
RCUS Stock Quote Price and Forecast - CNN
Arcus Biosciences prices $250M offering - MSN
Should you hold or exit Arcus Biosciences Inc. nowJuly 2025 Reactions & Free Reliable Trade Execution Plans - newser.com
Arcus Biosciences (RCUS) Launches $250M Public Offering - GuruFocus
How moving averages guide Arcus Biosciences Inc. trading2025 Valuation Update & Growth-Oriented Investment Plans - newser.com
Arcus Biosciences prices $250 million public offering at $18.25 per share - Investing.com Australia
Arcus Biosciences says it announces pricing of $250 million public offering of common stock - MarketScreener
Arcus Biosciences (NYSE: RCUS) prices $250M stock offering of 13.7M shares - Stock Titan
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock - MarketScreener
Arcus Biosciences (RCUS) Engages Investment Banks for New Offeri - GuruFocus
Arcus Biosciences falls on stock offering launch - TradingView
Arcus Biosciences launches public offering of common stock - Investing.com
Arcus Biosciences announces launch of public offering - MSN
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):